Novartis AG ADR (NVS)vsRapid Micro Biosystems Inc (RPID)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
RPID
Rapid Micro Biosystems Inc
$1.99
0.00%
HEALTHCARE · Cap: $99.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 164447% more annual revenue ($56.58B vs $34.38M). NVS leads profitability with a 23.9% profit margin vs -145.8%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
RPID
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for RPID.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RPID
Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : RPID
The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while RPID is a turnaround play — different risk/reward profiles.
RPID carries more volatility with a beta of 1.46 — expect wider price swings.
RPID is growing revenue faster at 11.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rapid Micro Biosystems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology company focused on revolutionizing microbiological quality control processes within the pharmaceutical and biotechnology industries. Utilizing state-of-the-art automated growth-based microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, which is vital for adhering to stringent regulatory standards. As demand for rapid and reliable quality assurance solutions continues to grow, Rapid Micro is well-positioned to drive advancements in testing methodologies that are essential for maintaining product safety and excellence in highly regulated environments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?